Hoberman Kenneth is a corporate insider at STEMLINE THERAPEUTICS INC (STML) filing SEC Form 4 transactions. 90 transactions across 3 companies, totaling $126,375 in purchases and $5,776,373 in sales. Source: SEC EDGAR.
Insider trading profile for Hoberman Kenneth: PRINCIPAL = Stemline Therapeutics (STML, 73 tx, 2009-2020): 513,866 SELL vs 2,000 BUY = 257:1 ratio. Systematic distribution during Feb 2020 exit event: 600K A-code award at $0 + 1.37M U-code distribution + D-code 44K + D-code 25K + S-code liquidations at $4.91-$10.97 in Q1 2020 -- this is the STEMLINE tender-offer/exit conversion. Zero STML activity post-June 2020. Secondary = TG Therapeutics (TGTX, 12 tx, 2015-2026): 92,293 A-code acquisitions at $0 FMV spanning 2020-2026: 15K (Jun 2020), 20K (Jun 2021), 43.7K (Jul 2022), 20K (Sep 2023), 22.2K (Jun 2024), 14.7K (Jun 2025), 8.3K (Jun 2026) -- consistent annual/bi-annual grant receipts with no sells. Nuvectis Pharma (NVCT, 5 tx, 2022-2025): 51K A-code at $0 (15K Apr 2022 + 18K Jun 2023 + 30K Jun 2024 + 30K Jun 2025) + 6K P-code at $17.40 (May 2022) -- a small but fully discretionary open-market purchase at a deep early-stage valuation when the stock was a preclinical microcap. KEY SIGNAL: Post-STEMLINE exit, the insider rebuilt a concentrated gene-therapy/dermatology cluster (TGTX biotech success + NVCT deep-early-stage). The NVCT $17.40 P-code buy at a sub-$20 preclinical price ($17.40 × 6K = $104K personal commitment) is bullish on NVCT specifically. Classification: bullish on the TGTX/NVCT cluster; the STEMLINE history is exhausted and unrelated to current signal. Net: the A-code-only build-up across two overlapping oncology vehicles corroborates a personal-conviction allocation post-exit.
Source: SEC EDGAR Form 4 insider transaction filings.
Company | Type | Shares | Price | Value | Shares After | Date | SEC |
|---|---|---|---|---|---|---|---|
| Award | 8,325 | - | - | 8,325 | 6/11/2026 Filed: 6/11/2026 | Filing → | |
| Award | 14,718 | - | - | 279,653 | 6/12/2025 Filed: 6/16/2025 | Filing → | |
| Award | 30,000 | - | - | 133,140 | 6/12/2025 Filed: 6/12/2025 | Filing → | |
| Award | 22,250 | - | - | 264,935 | 6/19/2024 Filed: 6/20/2024 | Filing → | |
| Award | 30,000 | - | - | 103,140 | 6/13/2024 Filed: 6/13/2024 | Filing → | |
| Award | 20,000 | $0.00 | $0 | 242,685 | 9/28/2023 Filed: 9/29/2023 | Filing → | |
| Award | 18,000 | $0.00 | $0 | 73,140 | 6/16/2023 Filed: 6/20/2023 | Filing → | |
| Award | 43,732 | $0.00 | $0 | 222,685 | 7/20/2022 Filed: 7/22/2022 | Filing → | |
| Purchase | 6,000 | $17.40 | $104K | 55,140 | 5/12/2022 Filed: 5/16/2022 | Filing → | |
| Award | 15,000 | $0.00 | $0 | 15,000 | 4/1/2022 Filed: 4/5/2022 | Filing → | |
| Award | 20,000 | $0.00 | $0 | 178,953 | 6/18/2021 Filed: 6/22/2021 | Filing → | |
| Award | 15,000 | $0.00 | $0 | 158,953 | 6/22/2020 Filed: 6/24/2020 | Filing → | |
STEMLINE THERAPEUTICS INC STML | Disposition | 44,058 | - | - | 0 | 6/10/2020 Filed: 6/10/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Disposition | 25,000 | - | - | 0 | 6/10/2020 Filed: 6/10/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | U | 1,374,352 | - | - | 0 | 6/10/2020 Filed: 6/10/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Award | 600,000 | $0.00 | $0 | 1,374,352 | 6/10/2020 Filed: 6/10/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Sale | 16,704 | $4.91 | $82K | 771,764 | 3/10/2020 Filed: 3/13/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Sale | 9,487 | $5.08 | $48K | 788,468 | 3/9/2020 Filed: 3/13/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Sale | 11,547 | $6.42 | $74K | 797,955 | 2/25/2020 Filed: 2/28/2020 | Filing → |
STEMLINE THERAPEUTICS INC STML | Award | 208,417 | $0.00 | $0 | 809,502 | 2/10/2020 Filed: 2/14/2020 | Filing → |
Try asking...